De marca
Cuprimine, el original
No encontramos una tarjeta de ahorro ni un precio sin seguro del fabricante de Cuprimine. Pregunte en la farmacia el precio sin seguro de Cuprimine. Si tiene seguro, pregunte cuánto le cobra su plan.
Nombre genérico: penicillamine
Se usa para: Enfermedad de Wilson (exceso de cobre en el cuerpo) · Cálculos de cistina en las vías urinarias (cistinuria) · Artritis reumatoide grave · 2 más
Precio más bajo
$125.56 por 30 cápsulas
Penicillamine genérico 250 mg con la Team Cuban Card gratis, en farmacias que la aceptan
Un genérico regular tiene el mismo ingrediente activo que Cuprimine, y la FDA exige que funcione de la misma manera.
Cuprimine, el original
No encontramos una tarjeta de ahorro ni un precio sin seguro del fabricante de Cuprimine. Pregunte en la farmacia el precio sin seguro de Cuprimine. Si tiene seguro, pregunte cuánto le cobra su plan.
Antes se vendía uno, pero ya no.
El mismo ingrediente activo que Cuprimine. Los rellenos y colorantes pueden variar.
Precios sin seguro que publica cada farmacia para penicillamine genérico, del más bajo al más alto.
Recoger en tienda
Del sitio web de cada farmacia, consultado el 17 de noviembre de 2026. Confirme el precio antes de surtir su receta.
Los precios cambian, pueden variar según la tienda y el estado, y pueden depender de la concentración y de cuántas toma. Si tiene seguro, pregunte cuánto le cobra su plan; puede ser menos.
4 compañías venden un genérico de Cuprimine que la FDA califica como sustituto. La farmacia surte el que tenga. Para recibir el de un fabricante en particular, pídalo por su nombre; la mayoría de las farmacias lo pueden pedir en uno o dos días.
Lo surten sobre todo farmacias especializadas. El consultorio de su médico o su aseguradora le pueden decir cuál usar.
Fabricado por Watson Laboratories
250 mg Blanca a blanquecina, en forma de cápsula, 19 mm, marcada con “A98”
| Empaque | NDC |
|---|---|
| Frasco de 100 | 0591-4171-01 |
Ingredientes inactivos (en inglés, como en la etiqueta): magnesium stearate, mannitol, gelatin, sodium lauryl sulfate, titanium dioxide, ferrosoferric oxide, potassium hydroxide, propylene glycol, shellac
Contiene lactosa · Contiene un colorante: D&C Yellow No. 10
Página del producto en breckenridgepharma.com
250 mg Marfil, en forma de cápsula, 19 mm, marcada con “DP / 250”
| Empaque | NDC |
|---|---|
| Frasco de 100 | 51991-974-01 |
Ingredientes inactivos (en inglés, como en la etiqueta): D&C Yellow No. 10, gelatin, lactose monohydrate, magnesium stearate, titanium dioxide, shellac, ferrosoferric oxide, potassium hydroxide
Contiene lactosa · Contiene un colorante: FD&C Yellow No. 6
250 mg Crema claro, en forma de cápsula, 19 mm, marcada con “GPI250mg / 907”
| Empaque | NDC |
|---|---|
| Frasco de 100 | 70010-907-01 |
Ingredientes inactivos (en inglés, como en la etiqueta): ammonia, anhydrous lactose, ferrosoferric oxide, FD&C Yellow No. 6, gelatin, magnesium stearate, propylene glycol, shellac, titanium dioxide
Contiene lactosa · Contiene un colorante: D&C Yellow No. 10 · Fabricado por PH Health
250 mg Amarillo pálido, en forma de cápsula, 19 mm, marcada con “PAR / 146”
| Empaque | NDC |
|---|---|
| Frasco de 100 | 49884-146-01 |
Ingredientes inactivos (en inglés, como en la etiqueta): lactose monohydrate, magnesium stearate, D&C Yellow No. 10, gelatin, titanium dioxide, ferrosoferric oxide, potassium hydroxide, shellac
Quién lo vende: registros de la FDA y de Medicaid, actualizados cada semana. La página, la tarjeta y el programa de cada fabricante vienen de su propio sitio web.
CUPRIMINE is indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis.
Wilson’s Disease
Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal-recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology.
Two types of patients require treatment for Wilson’s disease: the symptomatic, and the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated.
The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is less than 20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (greater than 250 mcg/g dry weight) or Kayser-Fleischer rings are present.
Treatment has two objectives:
to minimize dietary intake of copper;
to promote excretion and complex formation (i.e., detoxification) of excess tissue copper.
The first objective is attained by a daily diet that contains no more than 1 or 2 mg of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient’s drinking water contains more than 0.1 mg/L of copper.
For the second objective, a copper chelating agent is used.
In symptomatic patients, this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances.
Clinical experience to date suggests that life is prolonged with the above regimen.
Noticeable improvement may not occur for 1 to 3 months. Occasionally, neurologic symptoms become worse during initiation of therapy with CUPRIMINE. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS). If the neurological symptoms and signs continue to worsen for a month after the initiation of CUPRIMINE therapy, several short courses of treatment with 2,3 - dimercaprol (BAL) while continuing CUPRIMINE may be considered.
Treatment of asymptomatic patients has been carried out for over 30 years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with CUPRIMINE is continued.
Cystinuria
Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal-recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: defective gastrointestinal absorption and renal tubular dysfunction.
Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities.
Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria.
Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated.
Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine-specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS).
When these measures are inadequate to control recurrent stone formation, CUPRIMINE may be used as additional therapy, and when patients refuse to adhere to conventional treatment, CUPRIMINE may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillamine-cysteine mixed disulfide as:
In this process, it is assumed that the deprotonated form of penicillamine, PS’, is the active factor in bringing about the disulfide interchange.
Rheumatoid Arthritis
Because CUPRIMINE can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids, should be used, when indicated, in conjunction with CUPRIMINE (see PRECAUTIONS).
Fuente: la etiqueta de la FDA de Cuprimine (Bausch Health US, LLC), 26 de enero de 2026. Etiqueta completa en DailyMed
Precios consultados el 17 de noviembre de 2026. Los precios cambian: confírmelos con la farmacia antes de surtir su receta. drugalt.com/es/drug/cuprimine/